menu
    • menu

    Company profile for Alkaloids Bioactives Private Limited

    Mix Gif-PSE
    News
    Gilead Sciences Completes Acquisition of Tubulis

    22 May 2026

    // PHARMIWEB

    Gilead Renews WHO Partnership to Fight Deadly Kala-Azar

    22 May 2026

    // FIERCE PHARMA

    Kelun, Merck's Lung Cancer Combo Boosts Late-Stage Survival

    22 May 2026

    // REUTERS

    DATA COMPILATION
    #PharmaFlow

    #1

    Contact Supplier

    Website

    PEGS Boston Summit

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/prostaglandin-market-to-cross-us-1-27-bn-by-2035-liquidia-s-yutrepia-okayed-for-pulmonary-hypertension

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Alkaloids Bioactives: US FDA, TGA & ISO-Certified Pioneers in Plant-Derived APIs, Nutraceuticals & Cosmeceuticals

    Related CompaniesRelated Companies

    About

    Alkaloids Bioactives specializes in manufacturing plant-derived Active Pharmaceutical Ingredients (APIs), nutraceuticals, and cosmeceuticals. With decades of experience, the company delivers sustainable, high-quality botanical solutions through expertise in standardized natural extracts. By combining scientific research, quality control, and regulatory compliance, Alkaloids Bioactives supports global healthcare and wellness markets as a reliable partner to pharmaceutical, nutraceutical, and cosmeceutical companies. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alkaloids Bioactives Private Limitedindia-flag Flag
    Country
    Country
    India
    Address
    Address
    834(P) Medchal Shamirpet Road, Medchal Mandal, Medchal-Malkajgiri District, PI...
    Telephone
    Telephone
    +91 9866242296
    Client Email
    Email
    info@alkaloids.co.in
    Client Website
    Website
    https://alkaloidsbioactives.com/
    Linkedin
    Linkedin
    http://www.linkedin.com/company/alkaloids-bioactives-private-limited
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/alkaloids-bioactives-party-content-56802.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Regulatory Approvals

    read-more

      https://www.pharmacompass.com/pdf/party/content/alkaloids-bioactives-private-limited-party-content-10174.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    PharmaCompass is introducing a new regulatory update that tracks developments in Certificates of Suitability to the Monographs of the European Pharmacopoeia, referred to as CEPs. These certificates are a critical regulatory instrument in the global pharmaceutical supply chain.Also known as a Certification of Suitability (COS), CEPs are issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM), with or without inspection of the manufacturing site. A CEP must be renewed every five years from its original issue date to remain valid, regardless of any revisions made during the interim period. However, a CEP does not replace Good Manufacturing Practice certification.CEPs are recognized as a trusted reference for API quality, thereby simplifying global registration strategies. Apart from Europe, the CEP system is widely used by many regulatory authorities, including those in Canada, Australia, Brazil, Singapore and South Africa. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)CEP 2.0 enhances regulatory clarity, brings efficiency, global interoperability There are several types of CEPs, depending on the nature of the substance and evaluation. The most common type is the Chemical CEP, which confirms that a chemically synthesized API meets standards for purity and impurity control. Then there are Herbal CEPs for herbal substances and preparations.Another key category is the TSE CEP, which addresses risks associated with transmissible spongiform encephalopathies in animal-derived materials. In addition, there are Combined CEPs that may cover multiple aspects, such as chemical quality, TSE risk, and sterility. However, biological products such as vaccines and blood products fall outside the scope of the CEP framework.In 2023, the CEP system underwent a major transformation with the introduction of CEP 2.0, which marks a shift from a largely document-based system to a more structured, transparent, and digitally aligned model. This makes it easier for companies to manage compliance while improving trust among global regulators.While increasing data and compliance requirements for API manufacturers, CEP 2.0 enables better regulatory clarity, streamlined dossier integration, and stronger global acceptance. Overall, CEP 2.0 is designed to enhance regulatory clarity while making the system more efficient and globally interoperable. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Indian firms issued maximum CEPs; Sun Pharma and its subsidiaries, Jubilant Biosys top listIndia topped the charts for CEPs issued, both in terms of new CEPs and revisions in the first quarter (Q1) of 2026. Indian companies were issued 81 new CEPs in Q1 2026 (as against 40 in Q1 2025) and 203 revisions (as against 129 in Q1 2025). In comparison, Chinese companies were issued 42 new CEPs in Q1 2026 (against 25 in Q1 2025) and 53 revisions (against 67 in Q1 2025). Italy came a distant third, followed by Germany and Spain.India’s Sun Pharmaceuticals and its subsidiaries topped the list of companies with the maximum number of CEPs issued— while no new CEP was issued, 27 CEPs were revised in Q1 2026. At second place was Jubilant Biosys — 21 CEPs were revised in Q1 2026.In terms of products, the maximum CEPs were issued for amlodipine besylate (a calcium channel blocker used for treating hypertension), followed by sitagliptin phosphate (a type 2 diabetes medicine) and pregabalin (a drug used to treat neuropathic pain, fibromyalgia, seizures, and generalized anxiety disorder). Both amlodipine besylate and sitagliptin phosphate had not been issued new CEPs or revisions in Q1 2025. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)EDQM introduces new guidelines to accelerate CEP assessments The EDQM charges fees for various services related to CEPs that depend on the type of request or regulatory activity involved. In general, fees apply to handling CEP applications, revisions or renewals and for offering technical advice (where applicants seek scientific or regulatory guidance).In March 2026, the EDQM introduced two new guidelines aimed at accelerating CEP assessments. The first is a reliance-based assessment pathway, which allows regulators to leverage prior approvals from trusted authorities, such as those in the EU, UK, Australia, Canada, and the WHO pre-qualification program. The second is a fast-track assessment route designed to expedite reviews in situations such as medicine shortages and to support initiatives like the EU Critical Medicines Act.Timelines have been significantly compressed under these new pathways. Initial evaluations are completed within 46 working days, compared to up to 115 days under the standard procedure. Applicants are given 30 calendar days to respond to queries, after which regulators complete the final assessment within 23 working days.Another important regulatory update relates to electronic submissions. From April 1, 2026, the EDQM will reject non-compliant CEP applications at the point of submission. All applications must include a validated electronic Common Technical Document (eCTD) dossier along with a proper validation report, submitted in line with the updated Common European Submission Portal (CESP) guidelines. Taken together, these developments signal a more rigorous yet efficient CEP ecosystem. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Our viewThe shift to CEP 2.0 signals a move toward greater transparency, digitalization, and global regulatory alignment. Though enhanced disclosure and stricter e-submission requirements may increase the compliance burden, especially for smaller manufacturers, the long-term gains are expected to be significant. Going forward, companies that invest in data quality and regulatory readiness stand to gain from these changes.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2037

    https://www.pharmacompass.com/radio-compass-blog/cep-q1-2026-update-cep-2-0-edqm-s-new-guidelines-strengthen-ecosystem-indian-firms-top-list-of-ceps-issued

    #PharmaFlow by PHARMACOMPASS
    09 Apr 2026
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company
    Pop up

    Others

    read-more
    read-more

    ABOUT THIS PAGE

    Contact Alkaloids Bioactives and get a quotation

    Alkaloids Bioactives is a supplier offers 30 products (APIs, Excipients or Intermediates).

    Find Colchicine bulk with DMF offered by Alkaloids Bioactives

    Find Ajmaline bulk offered by Alkaloids Bioactives

    Find Reserpine bulk offered by Alkaloids Bioactives

    Find Thiocolchicoside bulk offered by Alkaloids Bioactives

    Find 5-Hydroxy Tryptophan bulk offered by Alkaloids Bioactives

    Find Andrographolide bulk offered by Alkaloids Bioactives

    Find Ashwagandha bulk offered by Alkaloids Bioactives

    Find Asiaticoside bulk offered by Alkaloids Bioactives

    Find Bakuchiol bulk offered by Alkaloids Bioactives

    Find Betulinic Acid bulk offered by Alkaloids Bioactives

    Find Boswellia Serrata bulk offered by Alkaloids Bioactives

    Find Caffeine bulk offered by Alkaloids Bioactives

    Find Carnosic Acid bulk offered by Alkaloids Bioactives

    Find Cascara bulk offered by Alkaloids Bioactives

    Find Centella Asiatica Triterpenes bulk offered by Alkaloids Bioactives

    Find Ginkgo Biloba bulk offered by Alkaloids Bioactives

    Find Green Coffee Extract bulk offered by Alkaloids Bioactives

    Find Green Tea Extract bulk offered by Alkaloids Bioactives

    Find Guggul Extract bulk offered by Alkaloids Bioactives

    Find Gymnema Sylvestre bulk offered by Alkaloids Bioactives

    Find Karanjin bulk offered by Alkaloids Bioactives

    Find Melilotus Officinalis bulk offered by Alkaloids Bioactives

    Find Melissa Officinalis bulk offered by Alkaloids Bioactives

    Find Mucuna Pruriens Extract bulk offered by Alkaloids Bioactives

    Find Pongamol bulk offered by Alkaloids Bioactives

    Find Pterostilbene bulk offered by Alkaloids Bioactives

    Find Rosmarinic Acid bulk offered by Alkaloids Bioactives

    Find Senega bulk offered by Alkaloids Bioactives

    Find Ursolic Acid bulk offered by Alkaloids Bioactives

    Find Valerian Officinalis bulk offered by Alkaloids Bioactives

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search